Extract
我们感谢Volpe博士质疑Sabina III研究的结果是否表明SABA处方与贫困哮喘结局之间的关联应被视为“cause or consequence”[1]。我们同意that causation cannot be assumed and stated this clearly as follows “this cross-sectional study does not permit an assessment of a causal link between SABA prescriptions and asthma outcomes and does not discount reverse causality; the results simply represent an association。” [2] But implying that high levels of SABA use is simply a “结果”也是对复杂问题的过度简化。首先,除了流行病学研究的一致结果外,还有许多机械研究,关于定期使用SABA对气道炎症生物标志物,气道高反应性,哮喘症状控制和加剧风险的负面影响,因此不排除病因[3,4]。此外,虽然逻辑上考虑高度使用症状的药物必须代表不良的控制,但我们会指出,我们论文的核心目的是评估不使用吸入器,而是临床医生的SABA处方并在柜台上购买。。这些是有关医师行为和对SABA的访问权限的系统性问题,面对过度使用和哮喘控制不良,甚至鼓励使用SABA使用,这与哮喘指南建议相反[5]。这 ”长列表” of recommendations for addressing this situation is therefore highly pertinent to the objectives of the paper and we agree that these may, and in fact are intended to have “profound implications …. for clinical practice and public health” [5–7]。
脚注
该手稿最近被接受在European Respiratory Journal。It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of theERJ在线的。请打开或下载PDF以查看本文。
Conflict of interest: Dr. Batemanmember of the Science Committee and Board of GINA and reports personal fees from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, Novartis, Orion, Regeneron Pharmaceuticals and Sanofi Genzyme.
利益冲突:Price博士与Amgen,Astrazeneca,Boehringer Ingelheim,Chiesi,Circassia,Mylan,Mundipharma,Mundipharma,Regeneron,Regeneron,Sanofi Genzyme,Teva Genzyme,Teva Pharmaceuticals and Thermofisher都有董事会成员资格;与Amgen,Astrazeneca,Boehringer Ingelheim,Chiesi,Glaxosmithkline(GSK),Mylan,Mylan,Mundipharma,Novartis,Novartis,Pfizer,Teva,Teva和Theravance与咨询协议;来自Astrazeneca,Boehringer Ingelheim,Chiesi,Circassia,Mylan,Mylan,Mundipharma,Nokipharma,Novartis,Novartis,Ffizer,Regeneron,Regeneron,呼吸效率Genofi Genofi Genafi Genazyme,Teva,Teva,Teva,TETEVA,TEVA,TETEVA,TEVA,从而,从阿斯利康,Boehringer Ingelheim,Circassia,Circassia,Mundipharma,Sanofi genafi and Teva,TEVA,TETEVA,TEVA,,赠款和无限制的资金(通过观察和务实研究所PTE LTD进行)和英国国家卫生服务局;从阿斯利康,Boehringer Ingelheim,Chiesi,Cipla,Gsk,Gsk,Kyorin,Mylan,Mylan,Mundipharma,Mundipharma,Novartis,Regeneron,Regeneron,Sanofi Genzyme和Teva支付讲座/演讲/演讲。从Mundipharma和Novartis开发教育材料的支付;从阿斯利康,Boehringer Ingelheim,Mundipharma,Mylan,Novartis和Thermofisher支付旅行/住宿/会议费用;诺华的患者入学或完成研究的资金;AKL研发有限公司的股票/股票期权,生产植物药物;拥有74%的社会企业最佳患者护理有限公司(澳大利亚和英国)和74%的观察和务实研究所PTE Ltd(新加坡); is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme and Health Technology Assessment; and was an expert witness for GSK.
Conflict of interest: Dr. Wang reports no disclosures.
Conflict of interest: Dr. Schonffeldt reports lectures on medical education and inclusion as a researcher on clinical study protocols funded by AstraZeneca, GSK, Teva, ITF Labomed, Boehringer Ingelheim and Sanofi Genzyme.
利益冲突:阿斯利康的Catanzaritiemployes博士。RJPVDV在GSK以及Astrazeneca的股票和期权上拥有股票。
利益冲突:阿斯利康(Astrazeneca)的Van der Valk雇员。RJPVDV在GSK以及Astrazeneca的股票和期权上拥有股票。
Conflict of interest: Dr. Beekman was an employee of AstraZeneca at the time the study was conducted and has shares in AstraZeneca.
- 已收到2022年1月14日。
- Accepted2022年1月19日。
- 版权所有©作者2022。用于复制权和权限联系权限{at} ersnet.org